Carriers of parkin mutations usually develop early-onset disease, even before the age of 40, with a slow and benign disease course and good response to the common PD therapeutic, L-DOPA.
However, BRAF mutations are thought to develop early in the pathogenesis of melanomas, and analyses of a series of paired primary and metastatic lesions from the same patients indicate that BRAF mutations are preserved in metastases (Omholt et al, 2003).
Patients with Parkin mutations present with levodopa-responsive Parkinson's disease accompanied frequently by motor fluctuations and dyskinesias that often develop early in the course of treatment.
Brain scans of 20 people with the mutation, aged between 18 and 26, already showed differences compared with those from 24 people who were not destined to develop early Alzheimer's.
While M184V is a common resistance mutation that develops early in the majority of patients failing regimens with 3TC or FTC, therapeutic options remain given its association with hyper-susceptibility to other NRTIs.
In a recently published series of 12 aHUS patients [ 9] only one had THBD mutation and he developed early recurrence after kidney transplantation without recovery of renal function.
Women with FSHR-inactivating mutations develop multiple follicles in the early primordial, primary, secondary and pre-antral stages, but no antral or pre-ovulatory follicles (as their development is FSH-dependent) and such mutations are rare causes of POI (Aittomaki et al., 1995; Doherty et al., 2002).
At an early age, those born with such mutations develop osteoporosis, atheroscelerosis, wizened skin, hair loss, and other features typical of the elderly.
As a footballer, he developed early.
